|
We had a fantastic time at this year’s SOT meeting in San Diego, connecting with peers, exploring new ideas, and sharing the latest GARD® data on skin and respiratory sensitization from our industry collaborations. Thank you to all our collaborative partners for the outstanding teamwork!
Bayer | Coty | ExxonMobil | GDIT | Haleon | J&J MedTech | Merck |
|
|
Dr Andy Forreryd and Dr Tim Lindberg of SenzaGen presented at SOT symposium sessions, demonstrating how GARD® supports sensitization assessment of biopesticides and complex mixtures.
|
|
| At SenzaGen's hosted session, guest speakers from Merck, GDIT, and J&J MedTech shared new GARD® data on respiratory sensitization and ISO 10993-10 compliance for medical devices. |
|
|
|
 |
The collaborative work within the International Dialogue for the Evaluation of Allergens (IDEA) has been recently published in Regulatory Toxicology and Pharmacology, presenting new peer-reviewed evidence on the application of New Approach Methodologies (NAMs) in quantitative risk assessment (QRA) of fragrance materials.
The study demonstrates that SenzaGen’s single-assay method GARD®skin Dose-Response, alongside the multiple-assay approaches, delivers PoDs that well align with established human and animal reference potency data, within the expected biological variability.
Read the full article |
|
|
 |
We are pleased to see another leading global cosmetics company adopt GARD®skin Dose-Response to assess safe use levels of ingredients with potential skin-sensitizing properties. Powered by genomics and machine learning, the assay can be used as a standalone method to support robust, science-driven product development.
Explore 3 typical use scenarios |
|
|
🌎 Conference: ITCASS and ERGECD meeting | Strasbourg, France | April 15-17
🎧 Webinar: Advancing NAMs for respiratory sensitization testing-SOT Recap | Apr 22
🌎 Conference: ESTIV Congress | Maastricht, the Netherlands | June 29-July 2 |
|
|
|
